Venture Rounds Help Promedior Advance Lead Program In Multiple Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
With orphan drug designation in Europe, lead indication may be prevention of scarring in glaucoma filtration surgery patients.
You may also be interested in...
$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.